In 2024 the company made a revenue of N/A a decrease over the revenue in the year 2023 that were of N/A. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2025 (TTM) | N/A | |
2024 | N/A | |
2023 | N/A | |
2022 | N/A | |
2021 | N/A | |
2020 | N/A | |
2019 | N/A | |
2018 | N/A | |
2017 | N/A | |
2016 | N/A | |
2015 | N/A | |
2013 | N/A | |
2012 | N/A | |
2011 | N/A | -100% |
2010 | NZ$0 M | -99.12% |
2009 | NZ$0.35 M | 314.25% |
2008 | NZ$0.08 M | -35.68% |
2007 | NZ$0.13 M | 115.94% |
2006 | NZ$0.06 M | 422.59% |
2005 | NZ$0.01 M | -356.76% |
2004 | -NZ$0.01 Million | -100.58% |
2003 | NZ$0.78 M | |
2000 | NZ$0 M | -98.84% |
1999 | NZ$0.38 M | 3.71% |
1998 | NZ$0.37 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
![]() Advaxis ADXS | NZ$0.19 M | N/A | ๐บ๐ธ USA |
![]() Corbus Pharmaceuticals
CRBP | N/A | N/A | ๐บ๐ธ USA |
![]() ImmunoGen
IMGN | NZ$0.48 B | N/A | ๐บ๐ธ USA |